Premium
Burkitt cell leukemia following treatment of Hodgkin's disease: Report of a case and review of the literature
Author(s) -
Krikler S. H.,
Bain G. O.,
Gordon P. A.
Publication year - 1984
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830170212
Subject(s) - medicine , lymphoma , leukemia , radiation therapy , disease , chemotherapy , oncology , cell , cancer research , pathology , immunology , biology , genetics
The development of Burkitt cell leukemia (FABL3) [1] in a patient 7 years after successful treatment of Hodgkin's disease (HD) by combined modality (chemotherapy and radiotherapy) therapy is described. The B‐cell nature of the leukemic blasts is shown by immunologic surface marker studies. While L3 leukemia is very rarely seen following therapy for HD, diffuse lymphoma of small noncleaved cells (LSNC)— resembling the Burkitt tumor—is more common in this setting.